Intensive rituximab regimen in immune‐mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment.

Intensive rituximab regimen in immune-mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment We focused on iTTP patients in clinical remission who failed to display improved ADAMTS13 activity following a standard treatment with rituximab.3 Patients were enrolled prospectively in our registry from January 2012 to July 2018 through the French Reference Center for Thrombotic Microangiopathies network (www.cnr-mat.fr). We report that an intensive rituximab regimen inspired by maintenance regimens of low-grade B-cell lymphomas allows improving ADAMTS13 activity in most cases (>75% of formerly unresponsive patients), with an acceptable safety profile. So far, only single cases previously supported the relevance of this strategy.10,11,12 Of interest, all three patients who did not respond to intensive therapy received a regimen consisting in a twice-a-year infusion of rituximab instead of the two- to three-month infusion regimen typically offered to the other patients. [Extracted from the article]